Literature DB >> 8476213

Influence of preoperative performance status on survival time of patients with advanced gastric cancer following noncurative resection.

Y Maehara1, K Sugimachi, M Ogawa, T Kakegawa, H Shimazu, M Tomita.   

Abstract

The relationship between preoperative performance status (PS) and the survival time of 152 patients with gastric cancer was determined following macroscopic noncurative resection and postoperative chemotherapy. There were no preoperative differences in laboratory data between the patients who led a normal life or those with a fully ambulatory performance status (PS 0 or 1) and those who were often bedridden (PS 2 or 3). Neither was there any difference between the groups with regard to clinicopathological factors. The doses of drugs prescribed were lower for patients with PS 2-3. There was no difference in the occurrence of drug toxicity between the groups. The patients with PS 0-1 had a significantly longer survival time than did those with PS 2-3 (P < 0.05). PS, a factor more easily measured than the stage of disease at the time of admission, correlates with survival time. We interpret our findings to mean that for patients with gastric cancer who are symptom-free or who are ambulatory with symptoms, clinical trials of drugs may prolong survival time.

Entities:  

Mesh:

Year:  1993        PMID: 8476213

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status.

Authors:  Jun-Eul Hwang; Ha-Na Kim; Dae-Eun Kim; Hyun-Jeong Shim; Woo-Kyun Bae; Eu-Chang Hwang; Sang-Hee Cho; Ik-Joo Chung
Journal:  Exp Ther Med       Date:  2012-07-23       Impact factor: 2.447

2.  A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.

Authors:  H-C Jeung; S Y Rha; S J Shin; J B Ahn; S H Noh; J K Roh; H C Chung
Journal:  Br J Cancer       Date:  2007-07-24       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.